Top Markets
Coin of the day
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
株式のランク #5575
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
株価
$36.98
最終同期: 2026-08-26
時価総額
$2.58B
変化(1日)
-0.67%
変化(1年)
55.51%
NL
取引 Pharvaris N.V. (PHVS)

カテゴリー

Pharvaris N.V.(PHVS)の配当利回りの履歴
Pharvaris N.V.(銘柄コード: PHVS)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Pharvaris N.V.(PHVS)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)